Resting state functional connectivity changes after MR-guided focused ultrasound mediated blood-brain barrier opening in patients with Alzheimer's disease.
Aged
Alzheimer Disease
/ diagnostic imaging
Blood-Brain Barrier
/ diagnostic imaging
Clinical Trials, Phase I as Topic
Connectome
Female
Humans
Magnetic Resonance Imaging
Male
Middle Aged
Nerve Net
/ diagnostic imaging
Parietal Lobe
/ diagnostic imaging
Prefrontal Cortex
/ diagnostic imaging
Time Factors
Ultrasonography, Doppler, Transcranial
Blood-brain barrier
Blood-brain barrier opening
Functional connectivity
MR-Guided focused ultrasound
Resting state functional MRI
Journal
NeuroImage
ISSN: 1095-9572
Titre abrégé: Neuroimage
Pays: United States
ID NLM: 9215515
Informations de publication
Date de publication:
15 10 2019
15 10 2019
Historique:
received:
12
12
2018
revised:
13
06
2019
accepted:
25
06
2019
pubmed:
30
6
2019
medline:
21
3
2020
entrez:
30
6
2019
Statut:
ppublish
Résumé
MR-guided focused ultrasound (MRgFUS) can temporarily permeabilize the blood-brain barrier (BBB), noninvasively, to allow therapeutics access to the central nervous system. However, its secondary and potential neuromodulation effects are not well understood. We aimed to characterize the functional impact of MRgFUS BBB opening in human subjects, based on the phase I trial in patients with Alzheimer's disease. We analyzed for changes in bilateral frontoparietal networks in resting state functional MRI from five subjects after BBB opening in the right frontal lobe. We found a transient functional connectivity decrease within only the ipsilateral frontoparietal network that was recovered by the next day. Additionally, baseline to month three comparisons did not reveal any significant differences from matched-controls from the Alzheimer's Disease Neuroimaging Initiative. Overall, MRgFUS may transiently affect neurologic function, but the functional organization is restored at one day and remains unchanged at three months. This first in human data has implications for the development of MRgFUS as a drug delivery platform to pathologic brain tissue and potential use for non-invasive neuromodulation.
Identifiants
pubmed: 31254646
pii: S1053-8119(19)30557-9
doi: 10.1016/j.neuroimage.2019.06.060
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
275-280Informations de copyright
Copyright © 2019 Elsevier Inc. All rights reserved.